Kappa Bioscience AS
Score · fiscal year 2025
80of 100
How to read this: the company is ahead of 96 % of companies in the Morning class Large in the same sector in 2025. What does this mean?
Rank in the Morning class Large: 13 of 315 · What are Morning company classes?
Place in the whole sector: 126 of 3,928 · Industri
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 92 and solidity 69 out of 100 among companies in the Morning class Large in the same sector in 2025. Methodology
Against the sector
Kappa Bioscience AS is 31 points above the median for companies in the Morning class Large in the same sector in 2025.
Median score 49 among 315 companies.
Against companies in the Morning class Large in the same sector in 2025: operating margin 33.1% (median 6.2%) and equity ratio 47.6% (median 33.2%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 664 MNOK | 1,143 MNOK |
| Operating margin | 33.1% | 6.2% |
| Profit margin | 31.3% | 6.5% |
| Return on assets | 26.0% | 11.6% |
| Equity ratio | 47.6% | 33.2% |
| Debt-to-equity | 1.10 | 1.99 |
| Current ratio | 2.25 | 1.31 |
| Revenue growth | 39.2% | 7.2% |
| Revenue per employee | 14.76 MNOK | 6.01 MNOK |
The median and “ahead of” refer to companies in the Morning class Large in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 80, Kappa Bioscience AS does better than 96% of companies in the Morning class Large in the same sector (315 companies) in 2025.
Score 2023–2025
- Kappa Bioscience AS
- Median: companies in the Morning class Large in the same sector
Kappa Bioscience AS has a score of 80 for 2025, rank 126 of 3,928 in the sector.
Strongest: Profitability: percentile 92 against peers, operating margin 33.1% against a median of 6.2%. Growth: percentile 91 against peers, revenue growth 39.2% against a median of 7.2%.
No area is clearly below its peers.
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
Kappa Bioscience AS had an operating margin of 33.1% and an equity ratio of 47.6% in 2025, and ranks 126 of 3,928 in Industri.
From 2024 to 2025: revenue grew by 39% and the operating margin fell from 35.6% to 33.1%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 458 MNOK and 1,622 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 1,622 MNOK |
| EV/EBIT | 8.0 | 1,550 MNOK |
| P/B | 1.0 | 458 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
No rules were triggered for this year.
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 8.4% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of 0.4%. Based on the 10 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 92 | weight 30% |
|---|---|---|
| Solidity | 69 | weight 25% |
| Liquidity | 86 | weight 15% |
| Growth | 91 | weight 15% |
| Consistency | 58 | weight 15% |
Durability: 75 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is Kappa Bioscience AS?
The operating margin was 33.1% in 2025, against a median of 6.2% among companies in the Morning class Large in the same sector. Return on assets was 26.0%.
How solid is Kappa Bioscience AS?
The equity ratio was 47.6% in 2025 (median 33.2%). Debt-to-equity was 1.10 (median 1.99).
What is the liquidity of Kappa Bioscience AS like?
The current ratio was 2.25 in 2025 (median 1.31).
How does Kappa Bioscience AS compare in Industri?
Kappa Bioscience AS ranks 126 of 3,928 in Industri for 2025. Among companies in the Morning class Large it is number 13 of 315. Revenue changed by 39.2% from the year before.
From the Central Coordinating Register
- Org. no.
- 990476357
- Legal form
- AS
- Sector
- Industri (10.890)
- Morning company class
- Large
- Employees
- 45 registered 10 October 2026
- Founded
- 18 October 2006 20 years in operation
- Share capital
- 1.52 MNOK
- Business address
- 4. etasje, Silurveien 2B, 0380 OSLO
- Municipality
- Oslo rank 63–220 of 357 in Norway
- Latest accounts filed
- 2025
- LEI
- 2549006YCLEWF12DIC27 not renewed (lapsed)
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
Loading roles …
Source: Central Coordinating Register, fetched 31 October 2026. Only names are shown.
- Parent company
- Parent not made public
Source: GLEIF (Global Legal Entity Identifier Foundation), fetched 30 October 2026. The parent is the one the company itself reported to GLEIF.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 2 November 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 80 | 65 | 80 | |
| Rank | 318 | 842 | 126 | |
| Operating margin | 34.0% | 35.6% | 33.1% | |
| Return on assets | 24.2% | 27.1% | 26.0% | |
| Equity ratio | 52.0% | 41.6% | 47.6% | |
| Current ratio | 2.42 | 1.17 | 2.25 | |
| Revenue growth | – | 39.9% | 39.2% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 341.1 MNOK | 477.3 MNOK | 664.3 MNOK |
| Operating profit | 115.8 MNOK | 170.1 MNOK | 219.8 MNOK |
| Profit before tax | 112.7 MNOK | 169.5 MNOK | 207.6 MNOK |
| Net profit | 93.1 MNOK | 130.8 MNOK | 162.2 MNOK |
| Financial expenses | 26.1 MNOK | 23.3 MNOK | 42.7 MNOK |
| Total assets | 574.3 MNOK | 711.7 MNOK | 964.0 MNOK |
| Current assets | 211.5 MNOK | 281.9 MNOK | 535.9 MNOK |
| Equity | 298.7 MNOK | 296.2 MNOK | 458.4 MNOK |
| Retained earnings | 214.4 MNOK | 211.9 MNOK | 264.9 MNOK |
| Total liabilities | 275.6 MNOK | 415.5 MNOK | 505.6 MNOK |
| Current liabilities | 87.2 MNOK | 240.7 MNOK | 238.1 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 2 November 2026, accounts id 7141507.
Further
Similar companies
- Norske Skog Saugbrugs AS index 82, rank 85 · compare
- Axel Andersen AS index 81, rank 95 · compare
- Norautron AS index 81, rank 111 · compare
- Framo Holsnøy AS index 80, rank 124 · compare
- Nordisk Aviation Products AS index 78, rank 195 · compare